12 January 2016 - Amgen Canada Inc., today announced that Health Canada has granted conditional approval of Blincyto (blinatumomab) for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B precursor acute lymphoblastic leukaemia.

For more details, go to: http://www.newswire.ca/news-releases/health-canada-approves-amgens-blincyto-blinatumomab-for-the-treatment-of-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia-564972561.html